TWIST BIOSCIENCE CORP (TWST)
US90184D1000 - Common Stock
TWST gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 586 industry peers in the Biotechnology industry. While TWST has a great health rating, there are worries on its profitability. TWST is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
TWST had negative earnings in the past year.
In the past year TWST has reported a negative cash flow from operations.
In the past 5 years TWST always reported negative net income.
In the past 5 years TWST always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -27.34%, TWST is doing good in the industry, outperforming 73.33% of the companies in the same industry.
The Return On Equity of TWST (-34.30%) is better than 76.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.34% | ||
| ROE | -34.3% | ||
| ROIC | N/A |
ROA(3y)-23.56%
ROA(5y)-32.67%
ROE(3y)-28.87%
ROE(5y)-39.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TWST's Gross Margin of 38.29% is fine compared to the rest of the industry. TWST outperforms 78.46% of its industry peers.
In the last couple of years the Gross Margin of TWST has grown nicely.
TWST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.74%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TWST does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TWST has been increased compared to 1 year ago.
Compared to 5 years ago, TWST has more shares outstanding
There is no outstanding debt for TWST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 9.21 indicates that TWST is not in any danger for bankruptcy at the moment.
TWST has a better Altman-Z score (9.21) than 85.47% of its industry peers.
TWST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.21 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
A Current Ratio of 5.51 indicates that TWST has no problem at all paying its short term obligations.
The Current ratio of TWST (5.51) is comparable to the rest of the industry.
TWST has a Quick Ratio of 5.06. This indicates that TWST is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 5.06, TWST perfoms like the industry average, outperforming 53.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.98% over the past year.
The Revenue has grown by 21.79% in the past year. This is a very strong growth!
TWST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 57.36% yearly.
EPS 1Y (TTM)16.98%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.04%
Revenue 1Y (TTM)21.79%
Revenue growth 3Y39.6%
Revenue growth 5Y57.36%
Revenue growth Q2Q25.13%
3.2 Future
Based on estimates for the next years, TWST will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.29% on average per year.
TWST is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.60% yearly.
EPS Next Y6.89%
EPS Next 2Y9.17%
EPS Next 3Y8.29%
EPS Next 5YN/A
Revenue Next Year21.39%
Revenue Next 2Y21.07%
Revenue Next 3Y20.6%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
TWST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TWST. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.17%
EPS Next 3Y8.29%
5. Dividend
5.1 Amount
No dividends for TWST!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TWIST BIOSCIENCE CORP
NASDAQ:TWST (5/17/2024, 7:00:01 PM)
After market: 47.01 0 (0%)47.01
+0.51 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.72B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.34% | ||
| ROE | -34.3% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 38.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.51 | ||
| Quick Ratio | 5.06 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)16.98%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y6.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)21.79%
Revenue growth 3Y39.6%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y